{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:22:44Z","timestamp":1770970964591,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and\/or depression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Subjects with bipolar disorder with \u22654 mood episodes in the past 12 months entered the open-label stabilization phase preceding a placebo-controlled, double-blind study. Subjects with significant depressive or manic\/mixed symptoms at baseline were analyzed. Significant depressive symptoms were defined as Montgomery-\u00c5sberg Depression Rating Scale (MADRS) \u226516 and Young Mania Rating Scale (YMRS) &lt; 16; manic\/mixed symptoms were YMRS \u226516 with any MADRS score. Subjects received open-label RLAI (25-50 mg every 2 weeks) for 16 weeks, adjunctive to a subject's individualized treatment for bipolar disorder (mood stabilizers, antidepressants, and\/or anxiolytics). Clinical status was evaluated with the Clinical Global Impressions of Bipolar Disorder-Severity (CGI-BP-S) scale and changes on the MADRS and YMRS scales. Within-group changes were evaluated using paired <jats:italic>t<\/jats:italic> tests; categorical differences were assessed using Fisher exact test. No adjustment was made for multiplicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>162 subjects who relapsed frequently met criteria for significant mood symptoms at open-label baseline; 59\/162 (36.4%) had depressive symptoms, 103\/162 (63.6%) had manic\/mixed symptoms. Most subjects (89.5%) were receiving \u22651 medication for bipolar disorder before enrollment. Significant improvements were observed for the total population on the CGI-BP-S, MADRS, and YMRS scales (p &lt; .001 vs. baseline, all variables). Eighty-two (53.3%) subjects achieved remission at the week 16 LOCF end point. The subpopulation with depressive symptoms at open-label baseline experienced significant improvement on the CGI-BP-S and MADRS scales (p &lt; .001 vs. baseline, all variables). Subjects with manic\/mixed symptoms at baseline had significant improvements on the CGI-BP-S and YMRS scales (p &lt; .001 vs. baseline, all variables). No unexpected tolerability findings were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Exploratory analysis of changes in overall clinical status and depression\/mania symptoms in subjects with symptomatic bipolar disorder who relapse frequently showed improvements in each of these areas after treatment with RLAI, adjunctive to a subject's individualized treatment. Prospective controlled studies are needed to confirm these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-244x-11-171","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T07:24:48Z","timestamp":1321601088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms"],"prefix":"10.1186","volume":"11","author":[{"given":"Wayne","family":"Macfadden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb M","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T","family":"Haskins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norris","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,28]]},"reference":[{"key":"912_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1176\/ajp.155.5.646","volume":"155","author":"PE Keck Jr","year":"1998","unstructured":"Keck PE, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P: 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry. 1998, 155: 646-652.","journal-title":"Am J Psychiatry"},{"key":"912_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0165-0327(02)00332-4","volume":"73","author":"LL Judd","year":"2003","unstructured":"Judd LL, Akiskal HS: The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Discord. 2003, 73: 123-131. 10.1016\/S0165-0327(02)00332-4.","journal-title":"J Affect Discord"},{"key":"912_CR3","first-page":"S91","volume":"11","author":"CL Bowden","year":"2005","unstructured":"Bowden CL: Bipolar disorder and work loss. Am J Manag Care. 2005, 11: S91-S94.","journal-title":"Am J Manag Care"},{"key":"912_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1176\/ajp.2006.163.9.1561","volume":"163","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS: Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006, 163: 1561-1568. 10.1176\/appi.ajp.163.9.1561.","journal-title":"Am J Psychiatry"},{"key":"912_CR5","first-page":"757","volume":"14","author":"KE Laxman","year":"2008","unstructured":"Laxman KE, Lovibond KS, Hassan MK: Impact of bipolar disorder in employed populations. Am J Manag Care. 2008, 14: 757-764.","journal-title":"Am J Manag Care"},{"key":"912_CR6","first-page":"1","volume-title":"Practice Guideline for the Treatment of Patients With Bipolar Disorder","author":"RMA Hirschfeld","year":"2002","unstructured":"Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, Wagner KD, Perlis RH: Practice Guideline for the Treatment of Patients With Bipolar Disorder. 2002, 1-82. Second","edition":"Second"},{"key":"912_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2165\/00023210-200519070-00001","volume":"19","author":"W Coryell","year":"2005","unstructured":"Coryell W: Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs. 2005, 19: 557-569. 10.2165\/00023210-200519070-00001.","journal-title":"CNS Drugs"},{"key":"912_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0165-0327(99)00196-2","volume":"61","author":"RJ Baldessarini","year":"2000","unstructured":"Baldessarini RJ, Tondo L, Floris G, Hennen J: Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Discord. 2000, 61: 13-22. 10.1016\/S0165-0327(99)00196-2.","journal-title":"J Affect Discord"},{"key":"912_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4088\/JCP.09m05514yel","volume":"71","author":"RH Perlis","year":"2010","unstructured":"Perlis RH, Ostacher MJ, Miklowitz DJ, Hay A, Nierenberg AA, Thase ME, Sachs GS: Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry. 2010, 71: 296-303. 10.4088\/JCP.09m05514yel.","journal-title":"J Clin Psychiatry"},{"key":"912_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.4088\/JCP.08m04408","volume":"70","author":"A Martinez-Aran","year":"2009","unstructured":"Martinez-Aran A, Scott J, Colom F, Torrent C, Tabares-Seisdedos R, Daban C, Leboyer M, Henry C, Goodwin GM, Gonzalez-Pinto A, Cruz N, Sanchez-Moreno J, Vieta E: Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry. 2009, 70: 1017-1023. 10.4088\/JCP.08m04408.","journal-title":"J Clin Psychiatry"},{"key":"912_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jad.2010.05.021","volume":"127","author":"L Gutierrez-Rojas","year":"2010","unstructured":"Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M: Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Discord. 2010, 127: 77-83. 10.1016\/j.jad.2010.05.021.","journal-title":"J Affect Discord"},{"key":"912_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2146\/ajhp080374","volume":"66","author":"M Hassan","year":"2009","unstructured":"Hassan M, Lage MJ: Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health-Syst Pharm. 2009, 66: 358-365. 10.2146\/ajhp080374.","journal-title":"Am J Health-Syst Pharm"},{"key":"912_CR13","first-page":"65","volume":"10","author":"JM Kane","year":"1995","unstructured":"Kane JM: Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Psychopharmacol. 1995, 10: 65-71.","journal-title":"Int Clin Psychopharmacol"},{"key":"912_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/15622970701530917","volume":"9","author":"E Vieta","year":"2008","unstructured":"Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, Bonet P: A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry. 2008, 9: 219-224. 10.1080\/15622970701530917.","journal-title":"World J Biol Psychiatry"},{"key":"912_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1399-5618.2009.00761.x","volume":"11","author":"W Macfadden","year":"2009","unstructured":"Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M, Mahmoud R: A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Dis. 2009, 11: 827-839. 10.1111\/j.1399-5618.2009.00761.x.","journal-title":"Bipolar Dis"},{"key":"912_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","volume":"68","author":"JA Quiroz","year":"2010","unstructured":"Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V: Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010, 68: 156-162. 10.1016\/j.biopsych.2010.01.015.","journal-title":"Biol Psychiatry"},{"key":"912_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389. 10.1192\/bjp.134.4.382.","journal-title":"Br J Psychiatry"},{"key":"912_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978, 133: 429-435. 10.1192\/bjp.133.5.429.","journal-title":"Br J Psychiatry"},{"key":"912_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","volume":"73","author":"MK Spearing","year":"1997","unstructured":"Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997, 73: 159-171. 10.1016\/S0165-1781(97)00123-6.","journal-title":"Psychiatry Res"},{"key":"912_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1192\/bjp.166.5.654","volume":"166","author":"SH Jones","year":"1995","unstructured":"Jones SH, Thornicroft G, Coffey M, Dunn G: A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995, 166: 654-659. 10.1192\/bjp.166.5.654.","journal-title":"Br J Psychiatry"},{"key":"912_CR21","volume-title":"Presented at the European Psychiatric Association 18th European Congress of Psychiatry, Munich, Germany","author":"S Montgomery","year":"2010","unstructured":"Montgomery S, Vieta E, Sulaiman AH, Cordoba R, Huberlant B, Schreiner A, Martinez G: Randomized, double-blind, placebo-controlled study of risperidone long-acting injectable in relapse prevention in patients with bipolar I disorder. Presented at the European Psychiatric Association 18th European Congress of Psychiatry, Munich, Germany. 2010"},{"key":"912_CR22","volume-title":"Value Health","author":"AR Rosa","year":"2010","unstructured":"Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, Comes M, Torrent C, Kapczinski F, Vieta E: Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010"},{"key":"912_CR23","unstructured":"Riperdal\u00ae Consta\u00ae [prescribing information]. 2010, Titusville, NJ: Ortho-McNeil Janssen"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-11-171\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T17:16:08Z","timestamp":1630516568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-11-171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,28]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-11-171","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,28]]},"assertion":[{"value":"20 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"171"}}